Who are Artemether-lumefantrine combination plus albendazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/artemether-lumefantrine-combination-plus-albendazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Artemether-lumefantrine combination plus albendazole — Competitive Intelligence Brief

Artemether-lumefantrine combination plus albendazole (Artemether-lumefantrine combination plus albendazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination with anthelmintic. Area: Infectious Disease.

marketed Antimalarial combination with anthelmintic Plasmodium falciparum (multiple mechanisms); Ascaris, Hookworm, Trichuris (tubulin) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Artemether-lumefantrine combination plus albendazole (Artemether-lumefantrine combination plus albendazole) — Navrongo Health Research Centre, Ghana. This combination kills malaria parasites through artemether's rapid parasite clearance and lumefantrine's sustained blood schizonticide activity, while albendazole eliminates co-occurring helminth infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artemether-lumefantrine combination plus albendazole TARGET	Artemether-lumefantrine combination plus albendazole	Navrongo Health Research Centre, Ghana	marketed	Antimalarial combination with anthelmintic	Plasmodium falciparum (multiple mechanisms); Ascaris, Hookworm, Trichuris (tubulin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination with anthelmintic class)

Navrongo Health Research Centre, Ghana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Artemether-lumefantrine combination plus albendazole — Competitive Intelligence Brief. https://druglandscape.com/ci/artemether-lumefantrine-combination-plus-albendazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab